Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Hep C Discussion Forum -> General Discussion -> GS-5816 new pangenotype NS5A inhibitor in mighty DAA combo trial
Post Info TOPIC: GS-5816 new pangenotype NS5A inhibitor in mighty DAA combo trial
Isiscat2011


Guru

Status: Offline
Posts: 1724
Date:
UPDATE on GS-5816
Permalink  
 

Zilkster:  This one looks pretty good for you, doesn't it?   Gilead just bought a shortcut voucher for faster FDA approval.  Maybe the voucher will be used on GS-5816 ??

 

November 25, 2014

Gilead's 8-Week Hep C Cure Is Good for Genotype 3, Not 1 or 2

 

 

Eight weeks of Gilead Sciences' Sovaldi and GS-5816, with or without ribavirin, cured high rates of people with genotype 3 of hepatitis C virus (HCV), but yielded unsatisfactory results among those with genotypes 1 and 2, MedPage Today reports. Researchers randomly divided 120 people with genotype 1, 103 people with genotype 2, and 102 people with genotype 3 into one of four groups: Everyone received Sovaldi, plus either 25 milligrams or 100 mg of the investigational NS5A inhibitor known as GS-5816, with or without ribavirin. They were all treated for eight weeks. Results were presented at the Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

Among those with genotype 1, 83 percent of the participants who took 25 mg of GS-5816 plus ribavirin achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure), compared with 81 percent of those who took 100 mg with ribavirin. In the arms that did not receive ribavirin, 87 percent of those who took 25 mg of GS-5816 were cured, compared with 90 percent of those who took 100 mg.

Among those with genotype 2 who did not take ribavirin, a respective 77 percent and 88 percent of the low and high doses of GS-5816 were cured. As for the genotype 2s who did take ribavirin, 88 percent of both those on the high and the low dose of GS-5816 achieved an SVR12.

Among those with genotype 3 who did not take ribavirin, a respective 100 percent and 96 percent of those in the low- and high-dose arms were cured. (One person in the high-dose arm withdrew consent to be in the study, which is why that cure rate wasn't 100 percent.) As for the genotype 3s who did take ribavirin, 88 percent of those taking the low dose and 100 percent of those on the high dose were cured.

Adverse side effects among those with genotypes 1 and 2 were mostly mild to moderate. There were four serious adverse side effects. 

The adverse side effects for those with genotype 3 were mostly mild. There were two grade 3 or 4 side effects.

http://www.hepmag.com/articles/eight_weeks_2501_26497.shtml

http://www.npr.org/blogs/health/2014/11/19/365254707/gilead-buys-shortcut-for-fda-drug-review-for-125-million



__________________

Diagnosed in 2011, Incivek triple in 2011, tx discontinued, Genotype 1a, CT, VL 7mill, cirrhosis dx in 2012, age 67, waiting for new DAAs.
Isiscat2011


Guru

Status: Offline
Posts: 1724
Date:
RE: GS-5816 new pangenotype NS5A inhibitor in mighty DAA combo trial
Permalink  
 

Zlikster wrote:

Would Gilead risk to cannibalize it early or on purpose postpone GS5816 release until Ledi brings enough profit?

I feel quite comfortable in saying there is no f*****g way Gilead will pass on the opportunity to maximize profits by releasing Ledi asap and then take a second bite at the apple by releasing GS5816 when it is most advantageous to do so.  Timing is everything but this is a fluid situation so no way to predict with certainty.  

I would not put it past them to table a better drug but the better drug will potentially have even greater profitability.  Gilead wouldn't want to postpone it by much because other pharma combos will be getting some play depending on price.

Gilead will have an >2 month jump on Abbvie regardless of cost because S/L will be released first.  If S/L and Abbvie are priced comparably docs will still choose Gilead's S/L.  The GS5816 will arrive in time to treat and RETREAT harder-to-treat populations.  It doesn't get much better than that!

I'll keep my eyeballs peeled for clinical trials, Zilkster.  Anybody as committed as you is bound to kick the dragon's butt. :)



__________________

Diagnosed in 2011, Incivek triple in 2011, tx discontinued, Genotype 1a, CT, VL 7mill, cirrhosis dx in 2012, age 67, waiting for new DAAs.
Zlikster


Guru

Status: Offline
Posts: 791
Date:
Permalink  
 

I somehow missed their results from Astral-2 (back in April?):

"Study GS-US-342-0102 , is an ongoing randomized Phase 2 clinical trial in which treatment-naïve, non-cirrhotic patients with genotypes 1-6 HCV infection received a 12-week course of SOF plus the pan-genotypic NS5A inhibitor GS-5816. Patients received SOF 400 mg and either GS-5816 25 mg (n=77) or GS-5816 100 mg (n=77). In this study, 94.8 percent (n=73/77) of patients receiving the 25 mg dose of GS-5816 and 96.1 percent (n=74/77) of patients receiving the 100 mg dose achieved SVR12."

Can't find full report with info on genotype classification on those 144 patients that participated in it, but i would gladly "sacrifice" myself for their Phase III Astral-3 (600 patients) study ;) Too bad they do not show hospital locations, tho i figured out UK ones have address. Sent few emails to em. Keeping fingers crossed.


I wonder will they actually have any time to market properly Ledipasvir, considering GS5816 might be approved  as soon as late 2015/early 2016 and by the results, it's way more potent than Ledi or any other NS5A inhibitor. Would Gilead risk to cannibalize it early or on purpose postpone GS5816 release until Ledi brings enough profit?
Then again there is poor, left in the cold, BMS. They still need their own proper NS5B inhibitor to go with Daclatasvir and J&J's Simeprevir yields better results than Asuneprevir as NS3 inhibitor. Now their future from grim (Ledipasvir on market soon) got even grimmer with Gilead's pangenotype killer GS5816...wonder whats Merck doing? Waiting for Gilead to market SOF/LED for 1.5k $ per pill? :D









__________________

GT 3 dg. 08-2012 / FibroScan: 5 kPa F1 / FibroTest: F0-1 A1 / SoC TX: PegInt 120mcg+Riba 1000mg UND from w8 relapse EOT+4w
01-2016 Sof+Dac+Riba UND from w8, SVR24!
Tig


Admin

Status: Offline
Posts: 9284
Date:
Permalink  
 

When they are all addressed, someone, somewhere, will find something they left out biggrin...

Tig



__________________

Tig

68yo GT1A - 5 Mil - A2/F3 - (1996) Intron A - Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 9+ years!

Hep C FAQ   Lab Ref. Ranges  HCV Resistance

Signature Line Set Up/Abbreviations   Payment Assistance

 
Isiscat2011


Guru

Status: Offline
Posts: 1724
Date:
Permalink  
 

mallani wrote:

It's even effective against the S282T RAV generated by Sovaldi. 

 Oh, the irony.  

 Didn't Gilead state that the Sovaldi created RAVs will disappear on their own in a very short period of time?   



__________________

Diagnosed in 2011, Incivek triple in 2011, tx discontinued, Genotype 1a, CT, VL 7mill, cirrhosis dx in 2012, age 67, waiting for new DAAs.
mallani


Guru

Status: Offline
Posts: 3398
Date:
Permalink  
 

Hi Zlikster,

GS-5816 seems promising. Gilead claim it is a second generation NS-5A blocker, and is pan-genotype and effective against all known antiprotease RAV's, all known NS-5A RAV's and the baseline Y93H and A30K RAV's for  Geno 3. It's even effective against the S282T RAV generated by Sovaldi. Sounds too good to be true!

If the Trials back up those statements, Ledipasvir may have a very short life!! Find a Trial buddy.



__________________

Geno 1b, IL28B CT,  x3 prior relapser,  ex-cirrhotic, 75 yo, did 48 weeks with Victrelis/Peg./Riba.  VL 1.28m at start, UNDET. at 8 ,12 ,16 ,24 ,30  and 48 weeks.  EOT 15 Feb 2013 , UNDET. at EOT + 28 weeks. SVR!  Still Undet. at EOT +5 years

Malcolm
Tig


Admin

Status: Offline
Posts: 9284
Date:
Permalink  
 

Hey Zlikster,

Gilead seems to agree with you! I'm sure you've seen this but it's worth posting the link for those that haven't. Let's hope this next gen attempt is the one!

 

http://www.gilead.com/news/press-releases/2014/4/gilead-announces-phase-2-results-for-two-investigational-alloral-sofosbuvirbased-regimens-for-the-treatment-of-chronic-hepatitis-c

Tig



__________________

Tig

68yo GT1A - 5 Mil - A2/F3 - (1996) Intron A - Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 9+ years!

Hep C FAQ   Lab Ref. Ranges  HCV Resistance

Signature Line Set Up/Abbreviations   Payment Assistance

 
Zlikster


Guru

Status: Offline
Posts: 791
Date:
Permalink  
 

Considering Ledipasvir and Daclatasvir results for GT3 were pretty mediocre, new gen of NS5A inhibitor GS-5816 showed great results in Phase II (Astral 2) study. Could this be THE combo Sofosbuvir+GS-5816 for all genotypes?

Phase III study for us GT3s soon to start, wish Gilead would provide precise locations, not just cities :( i would gladly apply anywhere...

 

http://clinicaltrials.gov/ct2/show/NCT02201953

 

 



__________________

GT 3 dg. 08-2012 / FibroScan: 5 kPa F1 / FibroTest: F0-1 A1 / SoC TX: PegInt 120mcg+Riba 1000mg UND from w8 relapse EOT+4w
01-2016 Sof+Dac+Riba UND from w8, SVR24!
Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.
Hep C Discussion Forum -> General Discussion -> GS-5816 new pangenotype NS5A inhibitor in mighty DAA combo trial
Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.